Log In
BCIQ
Print this Print this
 

MEDI1814

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
Description mAb against beta amyloid 42
Molecular Target Beta amyloid 42
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$380.0M

$30.0M

$350.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/09/2016

$380.0M

$30.0M

$350.0M

Get a free BioCentury trial today